REG - Close Brothers Fin. - Publication of Pricing Supplement

Close BrothersAnnouncement

Yesterday 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260609:nRSI6199Ha&default-theme=true

RNS Number : 6199H  Close Brothers Finance PLC  09 June 2026

9 June 2026

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR ITS TERRITORIES OR TO, OR
FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS OR OTHERWISE THAN TO PERSONS TO
WHOM IT CAN LAWFULLY BE DISTRIBUTED

CLOSE BROTHERS FINANCE PLC

PUBLICATION OF PRICING SUPPLEMENT IN RELATION TO THE ISSUE BY CLOSE BROTHERS
FINANCE PLC OF £250,000,000 5.750 PER CENT. FIXED RATE NOTES DUE 10 SEPTEMBER
2031 (THE "NOTES") GUARANTEED BY CLOSE BROTHERS LIMITED UNDER THE EURO MEDIUM
TERM NOTE PROGRAMME

Close Brothers Finance plc (the "Issuer") today announces that it has
published the pricing supplement dated 8 June 2026 setting out details of the
£250,000,000 5.750 per cent. Fixed Rate Notes due 10 September 2031 (the
"Pricing Supplement").

The Notes were issued pursuant to the base admission particulars dated 27 May
2026, including all documents incorporated therein by reference (together, the
"Admission Particulars"), in connection with the Euro Medium Term Note
Programme of Close Brothers Finance plc. The Pricing Supplement should be read
in conjunction with the Admission Particulars.

To view the Pricing Supplement, please paste the following URL into the
address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/6199H_1-2026-6-9.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/6199H_1-2026-6-9.pdf)

For further information, please contact:

Maritz Carvalho

Head of Investor Relations

Close Brothers Limited

10 Crown Place

London EC2A 4FT

+44 (0)333 321 6100

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Pricing Supplement and the
Admission Particulars may be addressed to and/or targeted at persons who are
residents of particular countries (specified in the Pricing Supplement and the
Admission Particulars) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom the offer
contained in the Pricing Supplement and the Admission Particulars is not
addressed. Prior to relying on the information contained in the Pricing
Supplement and the Admission Particulars, you must ascertain from the Pricing
Supplement and the Admission Particulars whether or not you are part of the
intended addressees of the information contained therein.

In particular, neither this announcement nor the Pricing Supplement nor the
Admission Particulars shall constitute an offer to sell or the solicitation of
an offer to buy securities in the United States or in any other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to
registration, exemption from registration or qualification under the
securities law of any such jurisdiction.

The securities described in the Pricing Supplement and the Admission
Particulars have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "Securities Act") or any relevant
securities laws of any state of the United States. The securities may not be
offered or sold within the United States or to or for the account or benefit
of U.S. persons except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act. The Pricing
Supplement and the Admission Particulars may not be accessed from, or
transmitted in or into, the United States.

Your right to access this service is conditional upon complying with the above
requirements.

END.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKCBPDBKDBAK



            Copyright 2019 Regulatory News Service, all rights reserved